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Solid lipid nanoparticlesAbstract Quantitative determination of gatiﬂoxacin in tablets, solid lipid nanoparticles (SLNs)
and eye-drops using a very simple and rapid chromatographic technique was validated and devel-
oped. Formulations were analyzed using a reverse phase SUPELCO 516 C-18-DB, 50306-U,
HPLC column (250 mm · 4.6 mm, 5 lm) and a mobile phase consisting of disodium hydrogen
phosphate buffer:acetonitrile (75:25, v/v) and with orthophosphoric acid pH was adjusted to 3.3
The ﬂow rate was 1.0 mL/min and analyte concentrations were measured using a UV-detector at
293 nm. The analyses were performed at room temperature (25 ± 2 C). Gatiﬂoxacin was separated
in all the formulations within 2.767 min. There were linear calibration curves over a concentration
range of 4.0–40 lg.mL1 and correlation coefﬁcients of 0.9998 with an average recovery above
99.91%. Detection of analyte from different dosage forms at the same Rt indicates the speciﬁcity
and stability of the developed method.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Gatiﬂoxacin (GTX) is a synthetic broad spectrum ﬂuoroquin-
olone antibiotic obtained from nalidixic acid, used to treat
various a wide range of infectious diseases (Fig. 1). Fluoro-
quinolones are quinolones having ﬂuorine at the 6th position
of the naphthyridine ring. Published structure–activity data
show that the presence of ﬂuorine atom (F) at C6 position
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Figure 1 Chemical structure of gatiﬂoxacin (GTX).
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and Gram-positive pathogens (Arteseros et al., 2002). The
methyl substituent on the piperazine ring contributes to its
Gram-positive activity, prolongs the half-life allowing for once
daily dosing, provides metabolic stability as evident by pri-
mary renal elimination of unchanged drug, and may limit
potentially adverse interaction with the drug metabolizing
enzyme. GTX has a cyclopropyl group at the N1 position like
ciproﬂoxacin and sparﬂoxacin which boosts Gram negative
activity and provides some Gram positive activity. Like cipro-
ﬂoxacin and sparﬂoxacin, GTX has a cyclopropyl group at the
N1 position that enhances Gram-negative activity and pro-
vides some Gram-positive activity. GTX lacks the 2,4-diﬂuoro-
phenyl group at the N1 position that was postulated to induce
hepatic and hematologic toxicities associated with trovaﬂoxa-
cin and temaﬂoxacin, respectively. Most notably, GTX is
characterized by the presence of a methoxy (AOCH3) group
at the C8 position. This substituent also possessed by moxi-
ﬂoxacin, confers enhanced activity against DNA-gyrase and
Topoisomerase-IV (Fukuda and Hiramatsu, 1999) and may
be important in limiting the potential for the development of
bacterial resistance. In addition, lack of a halide at the C8
position reduces the potential for phototoxicity.
In pharmaceutical preparations quantitative determination
of ﬂuoroquinolones has been reported by several analytical
methods, like capillary electrophoresis (Flurer, 1997), UV
spectrophotometry (Gouda et al., 2008; Amin et al., 2007),
titrimetry (Belal et al., 1999), on-line solid phase extraction
and ﬂuorometric detection by HPLC (Tasso and Costa,
2007), stability indicating high-performance thin-layer chro-
matographic method for determination of GTX as bulk drug
(Motwani et al., 2006) and HPLC (Mirza et al., 2008). Liquid
chromatography with column switching technique for GTX
determination in serum was developed by Nguyen et al.,
2004, but column switching is a difﬁcult and multistep tech-
nique so it is not feasible in all analytical laboratories. Mostly
HPLC techniques were either very exhaustive or applicable in
the identiﬁcation of ﬂuoroquinolones in biotic ﬂuids, nourish-
ing animal products, feeds (supplements) and to a lesser extent,
in pharmaceutical formulations. Majority of the described
techniques involve troublesome mobile phase (buffers) and dif-
ﬁcult detection methods (ﬂuorescence or mass detectors)
(Samanidou et al., 2003 and Joshi, 2002). The main objective
of this procedure is to develop and validate an economical,
rapid and sensitive method for the quantitative determination
of the drug in commercial eye drops and tablets as well as pre-
pared solid lipid nanoparticles where all formulations contain-
ing the same ﬂuoroquinolone molecule gatiﬂoxacin could be
determined on a single chromatographic system at the wave-
length, 293 nm. Although other HPLC analysis methods for
GTX have been reported, this proposed method carries two
main advantages: (i) versatility proven by the validity of our
method to determine GTX level in different pharmaceuticalforms including bulk drug, tablets, eye drops, and solid lipid
nanoparticles (SLNs) using the very same deﬁned conditions
with the same mobile phase, and (ii) the method is consider-
ably fast where GTX retention time was as short as 2.67 min.
2. Materials and methods
2.1. Materials
Gatiﬂoxacin sesquihydrate was kindly gifted by Wockhardt
Pharmaceuticals, Aurangabad, India, and used as reference
standard without further puriﬁcation. Acetonitrile (Spectro-
chem Pvt. Ltd. Mumbai, India), orthophosphoric acid (CDH
Pvt. Ltd. New Delhi, India), methanol (MerkSpecialities,
Pvt. Ltd. Mumbai, India), and analytical grade disodium
hydrogen phosphate (CDH Pvt. Ltd. New Delhi, India) were
purchased. Milli-Q, Millipak 40, Millipore System was used
to purify water. Puriﬁcation of all solvents and solutions was
done by using the membrane ﬁlter (MilliporeMillex-HV ﬁlter
units, Durapore-PVDF, polyethylene, 0.45 lm pore size) and
degassed before use by ultrasonication (Ultrasonicator, PCI,
Mumbai, India). All other solvents used were of HPLC and
reagents were of analytical grade. Different pharmaceutical
dosage forms of different manufacturers, presented in Table 1
were used as samples for the analysis by the developed method.
2.2. Instrumentation and chromatographic conditions
Quaternary pump high pressure liquid chromatograph model
Shimadzu LC-9A, equipped with UV–visible detector model
SPP-6A, controlling system SCL-6B, connected to a micro-
computer with ‘‘Chemstation’’ Shimadzu Class LC-10 Ver-
sion 1:62 is used for integration and processing of
chromatograms. A reversed phase SUPELCO 516 C-18-
DB, 50306-U, HPLC Column of dimension 250 mm · 4.6 mm,
5 lm was used as the analytical column. All analysis was done
at ambient temperature (25 ± 2 C). The mobile phase is a
mixture of 0.02 M disodium hydrogen phosphate buffer:aceto-
nitrile (75:25, v/v) and using orthophosphoric acid pH was
adjusted to 3.3. The ﬂow rate was 1.0 mL.min1 and volume
of injection was 20 lL. Before using all solutions the mobile
phase was sonicated for 30 min and UV detection was per-
formed at 293 nm for GTX.
2.3. Calibration curves
Accurately weighed amount of standard of gatiﬂoxacin sesqui-
hydrate bulk, equivalent to 10 mg of free base was transferred
to a 100 mL volumetric ﬂask. The volume was completed with
the mobile phase. The prepared solutions were sonicated dur-
ing 30 min and ﬁltered through a membrane ﬁlter (0.45 lm).
Final concentration was 100 lg.mL1. Aliquots of each solu-
tion were accordingly diluted with the mobile phase in order
to obtain solutions with a ﬁnal concentration of 12 lg.mL1.
Every day solutions are prepared freshly. Ten different concen-
trations of GTX bulk (4, 8, 12, 16, 20, 24, 28, 32, 36 and
40 lg.mL1) were obtained of each standard solution and
diluted with mobile phase. 20 lL of each solution was injected
in the chromatographic system (n= 3) and mean values of
peak areas were plotted against concentrations.
Table 1 Commercial dosage forms and solid lipid nanoparticles (SLNs) of GTX used in the developed HPLC method.
Samples Drug/active molecule Manufacturers Pharmaceutical dosage form Brand names Batch number
ED-1 Gatiﬂoxacin sesquihydrate Ajantha Pharma Ltd. Eye drops 0.3%, w/v Gate eye drops CA 047A
ED-2 Gatiﬂoxacin base Cipla Ltd. Eye drops 0.3%, w/v Gatiquin eye drops G 70503
TAB-1 Gatiﬂoxacin base Cipla Ltd. Tablet 400 mg Gatiquin tablet D 80338
TAB-2 Gatiﬂoxacin base Dr. Reddy’s Lab. Tablet 400 mg Gaity tablet V 80306
SLN-A Gatiﬂoxacin sesquihydrate – Suspension 0.3%, w/v – –
SLN-B Gatiﬂoxacin sesquihydrate – Suspension 0.3%, w/v – –
SLN-C Gatiﬂoxacin sesquihydrate – Suspension 0.3%, w/v – –
SLN-D Gatiﬂoxacin sesquihydrate – Suspension 0.3%, w/v – –
Stability-indicating HPLC method for the analysis of gatiﬂoxacin 872.4. Method validation
Linearity refers to ‘‘the relationship of (the analyte) concentra-
tion and assay measurement’’ (USP, 2007). We evaluated line-
arity by calibrating the curves to calculate the coefﬁcient of
correlation and the intercept values. Moreover, method preci-
sion was evaluated through intraday and interday repeatabil-
ity. For this purpose, the interday and intraday variation for
GTX determination was carried out at different concentration
levels (4, 12, 18, 32 and 40 lg.mL1) and expressed in terms of
% RSD and standard error of mean (SEM). Recovery tests
were done to assess the accuracy of the described technique
by applying the technique to drug samples of familiar amounts
of GTX corresponding to 50, 100 and 150% of the GTX label
claim. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ) were calculated using Eqs. (1) and (2), respectively,
where SD is the average standard deviation of the curve and
a is the slope of the curve:
LOD ¼ 3:3 SD
a
ð1Þ
LOQ ¼ 10 SD
a
ð2Þ
Furthermore, robustness was assessed by minor intentional
modiﬁcations in the mobile phase volume ratio. Mobile phases
have different ratios of Na2HPO4 buffer:acetonitrile
(75:25 ± 2 mL), changing the pH of this mobile phase
(3.3 ± 0.2) and minor alterations in the ﬂow rate
(1.0 ± 0.2 mL.min1) were tried in the proposed method.
Robustness of the method was studied in triplicate at a GTX
concentration of 12 lg.mL1.
2.5. Selectivity and speciﬁcity
A stock solution containing 100 mg of GTX in 100 mL dis-
tilled water was prepared and used for forced degradation to
provide an indication of the stability and speciﬁcity of the
developed HPLC method. Thereafter, to 15 mL of GTX stock
solution, 15 mL of 1 N HCl and 15 mL of 1 N NaOH were
added separately. Similarly, to 15 mL of stock solution of
GTX, 15 mL of hydrogen peroxide (H2O2) (30%, v/v) was
added to evaluate oxidative degradation. This solution was
heated in boiling water bath for 10 min to completely remove
the excess of hydrogen peroxide. All mixtures were reﬂuxed
separately for 3 h at 80 C in the dark in order to prevent light
degradation. Then, 120 lL of each mixture was diluted sepa-
rately with the mobile phase to a ﬁnal concentration of
12 lg.mL1. GTX powder was stored at 100 C for 8 h under
dry heat to study the inherent stability of GTX from which astock solution was prepared as described earlier. 5 mL of the
prepared stock solution was diluted to 10 mL with the mobile
phase to a ﬁnal concentration of 50 lg.mL1. 1.2 mL of the
resultant solution was diluted up to 5 mL with the mobile
phase to get a concentration of 12 lg.mL1. Also, 5 mL of
the stock solution was diluted to 10 mL with the mobile phase
to reach 500 lg.mL1 and was exposed to UV-irradiation at
254 nm for 8 h in a UV-chamber. 120 lL of the irradiated solu-
tion was diluted up to 5 mL with the mobile phase to get a con-
centration of 12 lg.mL1. In all degradation studies, all
prepared dilutions were ﬁltered through Milli-Q ﬁlter unit
before injection into the HPLC system and the average peak
area of GTX after injection (12 lg.mL1) of three replicates
was obtained.
2.6. Kinetic study
Kinetic study was conducted to verify the drug stability in
solution, but not the stability of drug in the ﬁnished product.
Brieﬂy, 100 mg of GTX was dissolved in 100 mL distilled
water to prepare standard solution (1000 lg.mL1). 40 mL ali-
quots of each were transferred in two separate 100 mL double
necked round bottomed ﬂasks and mixed with 10 mL of 1 N
HCl and 1 N NaOH respectively, to get the ﬁnal concentration
800 lg.mL1. These ﬂasks were reﬂuxed at different tempera-
tures (40 C, 50 C, 60 C, 70 C and 80 C) for acidic and
alkaline degradation for different time intervals. At the speci-
ﬁed time, the contents of the ﬂask were neutralized to pH 7.0
using predetermined volumes of 1 N HCl and 1 N NaOH.
Accurately 1.5 mL contents of the ﬂask were quantitatively
transferred to 100 mL volumetric ﬂasks with the help of micro-
syringe, and were diluted appropriately up to 100 mL with the
mobile phase to get a solution of 12 lg.mL1 concentration of
drug for the quantitative estimation. 20 lL of each ﬁltered
solution was injected in to the HPLC system, and the concen-
tration of the non-degraded drug was calculated. Each exper-
iment was repeated three times at each time interval for
every temperature. Data were further processed and the degra-
dation kinetics constants were calculated.
2.7. Application of the developed HPLC method
2.7.1. Analysis of GTX in different dosage forms
Ten tablets of GTX of two brands, Gatiquin 400 mg (TAB-1)
and Gaity 400 mg (TAB-2) were weighed individually, tritu-
rated to acquire a homogeneous mixture. An accurately
weighed quantity of triturated mixtures equivalent to 10 mg
of freebase of both brands were transferred separately to
100 mL volumetric ﬂasks. The portions were completed with
Figure 2 Representative chromatogram of gatiﬂoxacin bulk drug showing retention time 2.767 min: (12 lg.mL1). Conditions: RP-
Supelco 516 C-18-DB, 50306-U, HPLC column (250 mm · 4.6 mm, 5 lm), mobile phase, Na2HPO4: MeCN (75:25, v/v); pH adjusted to
3.3 with orthophosphoric acid; ﬂow rate, 1.0 mL.min1; UV-detection of gatiﬂoxacin at 293 nm at temperature (24 ± 2 C).
Table 2 Linear regression data for the calibration curve
(n= 3).
Statistical parameters Data
Linearity range (lg/mL) 4–40
Correlation coeﬃcient (r2 ± SD) 0.9998 ± 0.0006
Slope of curve ± SD 118,423 ± 1439.91
Conﬁdence limit of slopea 114,846–122,001
SEM of slope 831.3591
Intercept of curve ± SD 120,390 ± 1979.62
Conﬁdence limit of intercepta 115,472–125,308
SEM of intercept 1142.97
a 95% conﬁdence limit.
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30 min to facilitate proper solubilization. Aliquots of each
solution were accordingly diluted with the mobile phase to a
ﬁnal concentration of 12 lg.mL1 of GTX. All samples were
ﬁltered through Milli-Q ﬁlter unit before injection into the
system. Gate Eye-drops (0.3%, w/v) as ED-1 and Gatiquin
Eye-Drops (0.3%, w/v) as ED-2 were used. The approach
adopted for the preparation of eye drop sample was close to
that of tablets. Appropriate dilutions were made with the
mobile phase to get a ﬁnal concentration of 12 lg.mL1 of
GTX. SLNs for the eye coded as SLN-A, SLN-B, SLN-C
and SLN-D prepared in our laboratory containing equivalent
amount of GTX (i.e. 0.3%, w/v). Accurately weighed amount
of each SLN containing equivalent amount of drug was dis-
solved in a mixture of acetone:chloroform (2.5:2.5, v/v) in
10 mL different volumetric ﬂasks, to ensure complete extrac-
tion of the drug, it was sonicated for 30 min and volume was
completed to 10 mL with chloroform. The resulting solution
was centrifuged at 14,000 rpm at 10 C (Cooling Centrifuge,
C24, REMI Instruments Ltd. Mumbai, India) for 30 min
and supernatants were obtained. Aliquots of each supernatant
were accordingly diluted with the mobile phase, in order to
obtain a resulting concentration of 12 lg.mL1 of drug. All
dilutions were ﬁltered through Milli-Q ﬁlter unit before injec-
tion into the HPLC system.
2.7.2. Analysis of accelerated stability samples
Among two marketed tablets, TAB-1 was stored in the stabil-
ity chamber at the accelerated stability conditions: 40 C,
50 C, 60 C, 70 C, and 80 C temperatures and at 75 ± 5%
RH for 6 months. Similarly, among the two marketed eye-
drops, ED-1 was chosen and exact volume of nanosuspension
of SLN-B (in 0.9%, w/v NaCl solution) was packed in screw-
capped high density polyethylene container and stored at the
same accelerated stability temperatures but at 20 ± 5% RH
for 6 months (Mathews and Wall, 2000). Testing samples were
withdrawn at time points: initial (zero time), 1st month, 3rd
month and 6th month and remaining amount of drug contents
were analyzed by the developed HPLC method.
3. Results and discussion
3.1. Method validation
In order to validate an efﬁcient method for analysis of drug in
pharmaceutical products, preliminary tests were performedwith the objective to select adequate and optimum conditions.
Parameters, such as detection wavelength, ideal mobile phase
and their proportions, optimum pH and concentration of the
standard solutions were exhaustively studied and the ﬂow rate
of 1 mL.min1 was selected after preliminary tests.
3.1.1. Development of the optimum mobile phase
The HPLC method was optimized to develop a stability indi-
cating assay method for the quantitative determination of gati-
ﬂoxacin from solid lipid nanoparticles, tablets and eye drops as
mentioned above. Solutions of pure drug and the degraded
products were injected in to the HPLC system and run in dif-
ferent solvent systems. Initially acetonitrile–water, acetoni-
trile–water–methanol and dihydrogen potassium phosphate
buffer-acetonitrile in varying ratios were tried. The mobile
phase 0.02 M dihydrogen potassium phosphate buffer:acetoni-
trile (65:35 and 75:25, v/v) gave good results with Rt= 3.525
and 2.925 min respectively for gatiﬂoxacin but the typical peak
was not sharp because of tailing. Substitution of 0.02 M, dihy-
drogen potassium phosphate buffer with 0.025 M disodium
hydrogen phosphate buffer improved the peak characteristics
and the quantity optimized was 75 mL. Finally, the mobile
phase consisting of 0.025 M disodium hydrogen phosphate
buffer:acetonitrile (75:25, v/v) gave a sharp and well-deﬁned
symmetrical peak at Rt= 2.767 min as shown in Fig. 2.
3.1.2. Calibration curves
The linear regression data for the calibration curves (n= 3) of
GTX at 293 nm (Table 2) showed a good linear relationship
Table 3 Intra-day and inter-day precision of the proposed HPLC method (n= 3).
Spiked concentration
(lg/mL)
Repeatability (intra-day precision) Intermediate (inter-day precision)
Measured concentration
(lg/mL) ± SD
RSD
(%)
SEM Measured concentration
(lg/mL) ± SD
RSD
(%)
SEM
4 4.079 ± 0.054 1.330 0.031 4.1057 ± 0.048 1.184 0.028
12 12.009 ± 0.123 1.027 0.071 11.775 ± 0.156 1.329 0.090
18 18.055 ± 0.101 0.559 0.058 17.857 ± 0.244 1.369 0.144
32 31.865 ± 0.383 1.202 0.221 31.706 ± 0.467 1.476 0.270
40 40.281 ± 0.363 0.902 0.209 40.255 ± 0.342 0.851 0.197
Table 4 Recovery as accuracy studies of the proposed HPLC method (n= 3).
Percent (%) of drug added
to analyte
Theoretical concentration
(lg/mL)
Concentration found
(lg/mL) ± SD
% RSD SEM % Recovery
0 12 12.02 ± 0.119 0.995 0.069 100.16
50 18 17.98 ± 0.025 0.139 0.014 99.91
100 24 24.10 ± 0.019 0.081 0.011 100.43
150 32 31.98 ± 0.113 0.354 0.065 99.94
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the peak area. No signiﬁcant difference was observed in the
slopes of standard curves (one way ANOVA, P> 0.05). The
observed equation of the straight line was found as;
y= 118423x+ 120390 with R2-value above 0.9998. Linearity
data showed concentration interval of gatiﬂoxacin in which the
intensity of the detector response is proportional to the con-
centration of the analyzed substance.
3.1.3. Precision
The measurement of the peak area which in turn gave the con-
centrations at ﬁve different spiked concentration levels of 4,
12, 18, 32 and 40 lg.mL1 showed low values of %RSD
(<1.47%) and very low values of the SEM (<0.27) for inter-
and intra-day variations (Table 3) suggesting an excellent pre-
cision of the developed HPLC method.
3.1.4. Recovery studies
The accuracy of the assay method was evaluated in triplicate at
four concentration levels 12, 18, 24 and 32 lg.mL1, i.e. (0, 50,
100 and 150%). The percentage of recoveries, %RSD andTable 5 Robustness of the developed HPLC method (12 lg/mL, n
Mobile phase composition
(Disodiumhydrogen phosphate
buﬀer:acetonitrile, pH = 3.3)
Mean area ± SD % RSD
(73:27, v/v) 1,502,388 ± 17129.44 1.141
(77:23, v/v) 1,476,562 ± 15021.72 1.017
Mobile phase ﬂow rate
(1.2 mL/min) 1,478,228 ± 9945.20 0.673
(0.8 mL/min) 1,494,895 ± 12146.76 0.812
pH of mobile phase
(pH = 3.5) 1,505,562 ± 12746.11 0.846
(pH = 3.1) 1,508,228 ± 11232.41 0.745SEM were calculated from the slope and y-intercept of the cal-
ibration curve obtained. The recovery values obtained were
between the range of 99.91–100.42% (Table 4) conﬁrming
accuracy of the developed method.
3.1.5. LOD and LOQ
The limit of detection and limit of quantiﬁcation was calcu-
lated by the method as described in section (preparation of
degradation products). The signal-to-noise ratios of 3.3:1 and
10:1 were considered as LOD and LOQ and were found to
be 0.507 and 1.538 lg.mL1, respectively, which indicated
the adequate sensitivity of the method.
3.1.6. Robustness of the method
When mobile phase components were intentionally altered as
much as ±2 mL each, practically no effect was observed in
the chromatogram and no signiﬁcant difference was observed
in the area and retention time (Rt). There was a minor delay
in the retention time when mobile phase ﬂow rate was reduced
to 0.8 mL.min1. There was no signiﬁcant difference in the
retention time but a slight increase in the area of the chromato-= 3).
SEM Retention time (Rt) ± SD % RSD SEM
9889.976 2.799 ± 0.015 0.530 0.009
8673.048 2.743 ± 0.009 0.348 0.006
5742.033 2.706 ± 0.011 0.416 0.005
7013.139 2.832 ± 0.043 1.547 0.025
7359.179 2.769 ± 0.020 0.731 0.012
6485.250 2.783 ± 0.011 0.377 0.006
Figure 3 Representative chromatograms of GTX after forced degradations: induced with 1 N HCl (a); with 1 N NaOH (b); with 30%
H2O2 (c) with UV at 254 nm (d) and dry heat (e) (12 lg.mL
1). Conditions: RP-Supelco 516 C-18-DB, 50306-U, HPLC column
(250 mm · 4.6 mm, 5 lm), mobile phase, Na2HPO4:MeCN (75:25, v/v); pH adjusted to 3.3 with orthophosphoric acid; ﬂow rate,
1.0 mL.min1; UV-detection of gatiﬂoxacin at 293 nm at temperature (24 ± 2 C).
90 I.A. Aljuffali et al.gram was observed when pH of the mobile phase was altered
in order ±0.2 units. The low values of SD, %RSD and
SEM along with almost unchanged Rt values of gatiﬂoxacin
obtained after introducing small deliberate changes as men-
tioned above in the method indicated the robustness of the
developed HPLC method Table 5.3.1.7. Selectivity and speciﬁcity
Forced degradation studies here may be considered as stability
indicating property and their results indicating the selectivity
and speciﬁcity of the developed method. The chromatograms
of the samples treated with acid, base, H2O2, dry heat, and
UV-light (254 nm), showed well-separated peaks of pure
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Figure 4 First-order plots for the degradation of gatiﬂoxacin
solution with 1 N HCl at various temperatures. 40 C ( ); 50 C
(n), 60 C (m), 70 C ( ), 80 C ( ).
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Figure 5 First-order plots for the degradation of gatiﬂoxacin
solution with 1 N NaOH at various temperatures. 40 C ( ); 50 C
(n), 60 C ( ), 70 C (d), 80 C ( ).
Table 6 Summary of forced degradation studies of gatiﬂoxacin (GTX) (12 lg/mL).
Exposure conditions Time (h) % GTX
recovery
Degradation products (%)
(± SD, n= 3)
Rt values for degradation
products (min)
Acid, 1 N HCl, reﬂuxed 3 57.32 DP1* (8.11%± 1.02), DP2* (34.57%± 8.19) 4.40, 5.81
Base, 1 N NaOH, reﬂuxed 3 78.21 DP1* (21.79%± 6.58) 4.54
H2O2 (30%, v/v), reﬂuxed 3 96.15 DP1
* (3.85%± 4.89) 4.39
UV (254 nm) 8 97.06 DP1* (2.94%± 3.56) 4.38
Dry heat (80 C) 3 98.10 Not detected Not detected
* DP1 and DP2 are the degradation products obtained in the forced degradation studies as shown in Fig. 3a–e.
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Degradants identiﬁcation was based on the comparison of
UV-spectra of ‘‘stressed samples’’ with that of the ‘‘standard
solution’’. Peaks of the degradation products were well
resolved from the drug peak and the number of degradation
products with their Rt values (Fig. 3). The number of degrada-
tion products with their Rt-values, content of GTX remaining,
and calculated percentage recovery are listed in Table 6.
Drug recovery at the level of 57.32% and 78.21% from the
acid- and base-stressed samples, respectively, suggests a signif-
icant degradation of the drug in acidic and basic conditions.
The peaks of degradation products were well resolved from
the drug peak. The chromatogram of the sample treated with
30% (v/v) H2O2 showed only one additional peak at Rt,
4.392 min. The area of the H2O2 degradation product peak
was signiﬁcant and accountable for 96.15% recovery of
GTX from the H2O2-stressed sample. The chromatogram of
the dry-heat stressed sample did not show the appearance of
any additional peak of degradants but showed 98.10% recov-
ery of GTX. Drug recovery at the levels of 97.06% for the UV-
exposed sample, showed that the drug is unstable more toward
the dry heat stressed degradation than UV-irradiation.
3.1.8. Stability indicating property of the developed method
The chromatograms of the acid degraded sample for gatiﬂox-
acin showed two additional peaks at Rt values of 4.4 and
5.8 min respectively (Fig. 3a). The chromatograms of the base
degraded sample showed one additional peak at Rt value of
4.542 min (Fig. 3b). The areas of the base-degraded product
peaks were found to be extremely small than the area of stan-
dard drug concentration (12 lg.mL1) indicating that gatiﬂox-
acin undergoes mild degradation under basic conditions (1 N
NaOH). Drug recovery at the level of 57.32% and 78.21% sug-
gests signiﬁcant degradation of gatiﬂoxacin in acidic condition
(1 N HCl) and basic condition (1 N NaOH) respectively.
The chromatogram of the sample of gatiﬂoxacin treated
with 30% (v/v) H2O2 showed only one additional peak at
Rt= 4.392 min. other than the standard gatiﬂoxacin peak at
Rt= 2.775 min. (Fig. 3c). The area of the H2O2-degraded
product peak was found to be extremely small than the area
of standard drug concentration (12 lg.mL1) and drug recov-
ery at the level of 96.15% suggesting the stability of gatiﬂoxa-
cin toward the oxidation induced degradation.
The chromatogram of the sample exposed to UV-light at
254 nm showed one additional peak at Rt= 4.383 min other
than the standard gatiﬂoxacin peak at Rt= 2.783 min
(Fig. 3d). Drug recovery at the level of 97.06%, indicated that
the drug is stable toward the UV-radiations for the exposure
period of 8 h under study. Under dry heat (80 C) conditionthe drug did not show any additional peak other than the stan-
dard gatiﬂoxacin peak at Rt= 2.817 min (Fig. 3e). Drug
recovery at the level of 98.1%, suggested that the drug is stable
toward dry heat for the exposure period of 3 h.
3.1.9. Kinetics investigation
The kinetics of degradation of gatiﬂoxacin was investigated in
1 N HCl and 1 N NaOH. Each experiment was repeated three
times at each temperature and time interval and mean concen-
tration of gatiﬂoxacin was calculated for each experiment. A
regular decrease in the concentration of gatiﬂoxacin with
increasing time intervals was observed for higher temperatures.
At the selected temperatures (40 C, 50 C, 60 C, 70 C and
80 C for acidic and alkaline degradation) the degradation
Table 7 Degradation rate constant (Kobs), half-life (t1/2), t90 and R
2 values for gatiﬂoxacin in solution.
Temperature (K) Kobs (h
1) a t1/2 (h)
b t90 (h)
c R2 for pseudo-ﬁrst order plots
In 1 N HCl
313 (40 C) 0.126 5.49 0.83 0.9917
323 (50 C) 0.161 4.30 0.65 0.9989
333 (60 C) 0.203 3.42 0.52 0.9930
343 (70 C) 0.238 2.91 0.44 0.9986
353 (80 C) 0.330 2.11 0.32 0.9964
In 1 N NaOH
313 (40 C) 0.081 8.55 1.30 0.9927
323 (50 C) 0.103 6.71 1.02 0.9921
333 (60 C) 0.124 5.62 0.85 0.9938
343 (70 C) 0.140 4.93 0.75 0.9987
353 (80 C) 0.151 4.58 0.70 0.9971
a Degradation rate constant.
b Half-life.
c Time for 90% potency left.
92 I.A. Aljuffali et al.process followed ﬁrst-order kinetics (Figs. 4 and 5). From the
slopes of the straight lines it was possible to calculate apparent
ﬁrst order degradation rate constant (Kobs), half-life (t1/2), t90
(i.e. time where 90% of original concentration of the drug is
left) and R2- values for pseudo ﬁrst order plots at each temper-
ature for acidic and alkaline degradation processes using the
developed HPLC method are given in Table 7. Data obtained
from ﬁrst-order kinetics treatment were further subjected to ﬁt
in Arrhenius equation:
logK ¼ logA Ea
2:303RT
ð3Þ
where, K is the rate constant, A the frequency factor, Ea the
energy of activation (cal.mol1), R the gas constant
(1.987 cal.K1 mol1) and T is absolute temperature (Kelvin).
Arrhenius plot shows the temperature dependence of the drug
in the form of a natural logarithm of the rate coefﬁcient versus
the reciprocal temperature. An Arrhenius plot is extremely
useful if data are determined experimentally. It also shows at
a glance if the scatter of the data points is small or large; if
there exists an Arrhenius relation at all (i.e. a straight line);
and if there are enough data points to get unambiguous values
for A and Ea. The plot of (2 + Log K) versus (1/T · 103) gave
the Arrhenius plot (Fig. 6), which was found to be linear in the
temperature range of 40–80 C. The correlation coefﬁcient for
the line ﬁttings was found to be 0.987 and 0.972, respectively,0
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Figure 6 Arrhenius plot for the degradation of gatiﬂoxacin
solution in presence of 1 N HCl (¤) and 1 N NaOH (n).for acidic and basic degradation process. The activation energy
(Ea) and the Arrhenius frequency factor (A
e) were calculated
for acidic and alkaline degradation processes. The degradation
rate constant of GTX in solutions at room temperature (K25)
was obtained by extrapolating to 25 C (where 1000/
T= 3.356) by inserting this into Eq. (3) and t1/2 and t90 are
calculated, respectively, the values are represented in Table 8.
3.2. Application of the developed method
3.2.1. Analysis of GTX in tablets, eye drops and SLNs
A single peak was observed in the chromatogram of gatiﬂoxa-
cin samples extracted from tablets, eye drops and prepared
solid lipid nanoparticles. There was no interference from the
excipients present in the tablets, eye drops and SLNs. The drug
content (%) with %RSD and SEM of all the tested samples are
given in Table 9. It may, therefore, be inferred that degrada-
tion of gatiﬂoxacin had not occurred in the formulations that
were analyzed by this method. The low %RSD value indicated
the suitability of this method for routine analysis of gatiﬂoxa-
cin in conventional and novel drug delivery systems.
3.2.2. Analysis of accelerated stability
The method of accelerated testing of pharmaceutical products
based on the principle of chemical kinetics, which could be
used as a measure of stability of the drug under the stressedTable 8 Summary of degradation kinetics of gatiﬂoxacin in
solution at 25 C (298 K).
Parameters 1 N HCl 1 N NaOH
Ea (kcal mol
1)a 1.363 · 103 1.024 · 103
K25 (h
1)b 8.265 · 102 6.414 · 102
t1/2 (h)
c 8.3846 10.8041
t90 (h)
d 1.2728 1.6401
Ae 1.0564 0.3618
a Activation energy.
b Degradation rate constant.
c Half-life.
d Time for 90% potency left.
e Arrhenius frequency factor.
Figure 7 First-order plots for the degradation of gatiﬂoxacin from different dosage forms: TAB-1 (A), ED-1 (B) and SLN-B (C) at
temperature ranges of 40–80 C. Arrhenius plots for gatiﬂoxacin degradation from different dosage forms (D).
Table 10 Summary of degradation kinetics of drug product at
25 C (298 K).
Parameters Formulations
TAB-1 ED-1 SLN-B
K25 (day
1)a 2.91 · 103 4.52 · 103 3.82 · 103
t1/2 (years)
b 5.355 4.092 4.785
t90 (years)
c 0.652 0.419 0.497
a Degradation rate constant.
b Half-life.
c Time for 90% potency left.
Table 9 Detailed analysis report of GTX in tablets, eye drops and solid lipid nanoparticles (SLNs).
Samples Theoretical concentration
(lg/mL)
Concentration found
(lg/mL) ± SD
% RSD SEM Drug content
(%)
Retention
(Rt) min
TAB 1 12.0 11.97 ± 0.076 0.637 0.044 99.77 2.758
TAB 2 12.0 12.02 ± 0.025 0.209 0.015 100.19 2.733
ED 1 12.0 12.01 ± 0.026 0.220 0.015 100.08 2.742
ED 2 12.0 12.00 ± 0.040 0.337 0.023 99.97 2.767
SLN-A 12.0 11.98 ± 0.025 0.211 0.014 99.81 2.817
SLN-B 12.0 12.04 ± 0.015 0.126 0.009 100.36 2.775
SLN-C 12.0 12.03 ± 0.031 0.254 0.018 100.22 2.767
SLN-D 12.0 11.99 ± 0.026 0.221 0.015 99.92 2.767
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tion, should be conducted to provide information for the label-
ing on the product, storage condition, and in-use period of the
constituted product. In general, a drug product should be eval-
uated under storage conditions that test its thermal stability
and some times, its sensitivity to moisture or loss of solvent.
Here the accelerated study was performed to calculate the shelf
life of the drug products. At temperatures 40 C, 50 C, 60 C,
70 C and 80 C the process of drug degradation followed ﬁrst-
order kinetics (Fig. 7A-Fig. 7C). From the slopes of the
straight lines the apparent ﬁrst order degradation rate constant
(Kobs), half-life (t1/2), t90 and R
2-values for ﬁrst order plots at
each temperature point were calculated and results are pre-
sented in Table 10. The obtained data from ﬁrst-order kinetics,
were ﬁtted in the Arrhenius equation as mentioned above. The
plots of Log K versus (1/T · 103) K, was linear in the temper-
ature range of 40–80 C (Fig. 7D). The correlation coefﬁcient
for the line ﬁttings was found to be 0.9994, 0.9979 and
0.9984 for TAB-1, ED-1 and SLN-B respectively, for the decayprocess. The decay rate constant at room temperature (K25) is
obtained by extrapolating to 25 C (where 1000/T= 3.356 K)
by inserting this into Eq. (3) as mentioned above also t1/2 and
t90 were calculated and values are presented in Table 10.
94 I.A. Aljuffali et al.4. Conclusion
The developed method was validated in terms of accuracy, pre-
cision and robustness. A good linear relationship was observed
for GTX in the concentration ranges of 4–40 lg.mL1. The
correlation coefﬁcient was found to be 0.9998. The inter-day
and intra-day precision results were good enough to indicate
that the proposed method was precise and reproducible. Prep-
aration of samples was easy and efﬁcient. UV detection at
293 nm was found to be suitable. The assay experiment
showed that the contents of gatiﬂoxacin estimated in the tablet
dosage form, eye drops and SLN were free from the interfer-
ence of excipients. This demonstrated that the developed
HPLC method was simple, fast as evidenced by short retention
time, precise, accurate, sensitive and efﬁcient and could be con-
veniently adopted for the routine quality control analysis of
gatiﬂoxacin from its pharmaceutical dosage forms and bulk
drug. The results of forced degradation studies imply that
the developed method is stability indicating.
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